Company profile
Forte Biosciences, Inc.
NASDAQ: FBRX · Healthcare · Biotechnology
#1095 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
26DFH 33DQ 15GM 13SS 56
v0.1 · 65/100 weight · provisional
↑ market scale, Altman-Z · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$69.4M
Employees
22
as of 2026-08-13
Market cap
$1.6B
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$36.0k$36.0k2019
Net income-$69.4M-$69.4M2025
Operating income-$70.7M-$70.7M2025
Total assets$82.8M$82.8M2025
Liabilities$21.8M$21.8M2025
Equity$61.0M$61.0M2025
Revenue trend
FY2018 – FY2019 · USD
FY18
FY18
FY18
FY19
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Forte Biosciences, Inc.’s revenue?
Forte Biosciences, Inc. booked $36.0k in FY2019 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -192708.3% net margin.
Peers · Healthcare
Oragenics, Inc.46DHi-Great Group Holding Company25DGridAI Technologies Corp.30DLyell Immunopharma, Inc.31DNanoLogix, Inc.——Mountain Valley MD Holdings Inc.——Neighbors
Dallas →Key facts
CEOPaul A. Wagner
SectorHealthcare
IndustryBiotechnology
HeadquartersDallas, TX
ExchangeNASDAQ: FBRX
Employees22
IPO date2017-04-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.